Notice NOT-DE-24-027 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-24-041 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement solicits research applications that propose implementation science methodology to embed existing evidence-based coordinated pain care models into a variety of public and private health care systems (HCS) where this type of care does not exist. Applications that combine comparative effectiveness studies of innovative coordinated care models with strong implementation science methodology to embed effective approaches into HCSs also are encouraged. This NOFO requires that the coordinated care model under study be embedded into the health care delivery system of the applicant institutions. Coordinated pain care approaches proposed for study should include interventions from multiple disciplines as described below and should aim to improve pain management based on the biopsychosocial model of pain. Emphasis should be on populations of patients with greatest need. This NOFO solicits applications from HCS who have resources and infrastructure to support research and implementation of study approaches in partnership with those HCS who lack research resources or experience and would benefit most from implementation of cost-effective coordinated pain care. HCS partners who serve populations that are under-represented in research are encouraged to apply. Models of coordinated care proposed by the study team should be aligned with health care resources of the participating HCS and should be informed through engagement of stakeholders including patients, providers, healthcare system executives, policy makers, and payors. The study teams must include health care providers from multiple disciplines and implementation scientists.

GBP75000 - GBP90000 per year: Immunocore: Immunocore (NASDAQ: IMCR) is a pioneering, commercial-stage T cell receptor biotechnology company whose purpose is to develop and commercialize a new Oxford, England

Negotiable: Oxford Nanopore Technologies: We are looking for a delivery-focused Senior Software Engineer to join our Instrument Core team. Oxford, England

Notice NOT-AT-24-045 from the NIH Guide for Grants and Contracts

Notice NOT-CA-24-057 from the NIH Guide for Grants and Contracts

Notice NOT-TR-24-026 from the NIH Guide for Grants and Contracts

Raytheon Technologies Corporate Headquarters: Date Posted: 2024-05-17 Country: United States of America Location: MA105: BBN Headquarters 10 Moulton Street , Cambridge, MA, 02138 USA Position R... Cambridge, Massachusetts

£40,223 - £44,722 per annum, inclusive of London Allowance (Grade 4): Barts Cancer Institute , Queen Mary University London: Applications are invited for a Postdoctoral Researcher to join the Translational Lymphoma Research group of Professor Jessica Okosun. Our lab aims... London, Greater London, England

£40,223 - £49,785: Barts Cancer Institute , Queen Mary University London: An exciting opportunity to join the Ciccarelli lab ( https://www.crick.ac.uk/research/labs/francesca-ciccarelli ) to study the drivers of cancer ev... London, Greater London, England

Notice NOT-OD-24-116 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-215 from the NIH Guide for Grants and Contracts. This is a non-competitive funding opportunity intended to fund a single award. The National Institute of Neurological Disorders and Stroke is announcing its intent to issue a single source cooperative agreementto the Hennepin Healthcare Research Institute to submit a renewal application to complete the phase II Hyperbaric Oxygen Brain Injury Treatment (HOBIT) clinical trial.

Undisclosed: CHA Medical·Bio Group: A global network of 91 institutions in 7 countries, we are recruiting global talent to lead K-Bio and healthcare. South Korea (KR)

Notice NOT-NS-24-018 from the NIH Guide for Grants and Contracts

Zifo: Zifo is hiring! We are searching for a talented Bioinformatics Analyst to join our team. This individual will collaborate closely with our Bioinfor... Cary, North Carolina

Alida Biosciences: Associate Director/ Director Bioinformatics Alida Biosciences is an early-stage, VC backed startup company in San Diego focused on developing novel... San Diego, California

Raytheon Technologies Corporate Headquarters: Date Posted: 2024-05-17 Country: United States of America Location: MA105: BBN Headquarters 10 Moulton Street , Cambridge, MA, 02138 USA Position R... Cambridge, Massachusetts

Notice NOT-HL-24-014 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-NS-25-010 from the NIH Guide for Grants and Contracts. This RFA is soliciting applications proposing placebo-controlled, clinical trials to determine the efficacy and safety of FDA approved monoclonal antibody therapies directed against amyloid compared to placebo in diverse "mixed dementia" populations with a focus on Lewy Body Dementias (LBD). In this NOFO the mixed-etiology dementias (MED) that are of interest and that are in scope are cognitive impairment and dementia cases positive for 1) canonical Alzheimers pathology biomarkers (for example, amyloid deposition assessed using positron emission tomography and/or low cerebrospinal fluid amyloid beta 42 combined with elevated phosphorylated tau; and 2) a clinical LBD diagnosis, i.e. Parkinsons disease dementia (PDD) and/or dementia with Lewy bodies (DLB). Bayesian approaches with response adaptive randomization to examine specific subgroups are encouraged. Successful applications will be powered to determine efficacy in diverse populations representative of the distribution of the disease in the United States by sex, race/ethnicity, and geographic distribution. Applications must include elements of patient and community engagement that are incorporated into all stages of program development and at all levels of the organizational structure.

Funding Opportunity RFA-ES-24-003 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to further the development of Technology-Enhanced Training Products for the health and safety training of hazardous materials (HAZMAT) workers; waste treatment personnel; skilled support personnel associated with an emergency/disaster; emergency responders in biological hazard response, infectious disease response, and medical waste cleanup; emergency responders in disasters; and worker resiliency training. Technology-enhanced training products as defined by the Worker Training Program (WTP) include, but are not limited to, supporting training through various venues such as online training, mobile device training, virtual reality, and serious gaming. These advanced technologies complement all phases of training that can enhance, supplement, improve, and provide health and safety training for hazardous materials workers. These products must complement the goals and objectives of the WTP. The major objective of the NIEHS WTP is to prevent work related harm by training workers in how best to protect themselves and their communities from exposure to hazardous materials. The financial support for this initiative comes directly from NIEHS Worker Education and Training Branch SBIR funds.